ClinicalTrials.gg
SuspendedNCT01512888LVXSCID-NDUpdated Nov 16, 2026

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

A Phase 1/2 interventional study of CL20-i4-EF1α-hγc-OPT and Busulfan in Severe Combined Immunodeficiency Disease, X-linked, sponsored by St. Jude Children's Research Hospital. Suspended at 3 sites in United States. Open to male participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by St. Jude Children's Research Hospital · Phase 1/2, Interventional, and Treatment

How we know

Why this study was suspended
voluntary hold
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
Up to 24 Months
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.

Planned enrollment
3rd of 11
28 · median 12
Started
2016
the only one that year
Phase 1/2
8 of 20
3 open now
Registered
14th of 20
by date
Lead sponsor
1 of 20
St. Jude Children's Research Hospital

Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 1/2, and was the 14th registered.

X-Linked Combined Immunodeficiency Diseases

28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.

Browse X-Linked Combined Immunodeficiency Diseases studies →

Open to participants now

5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: Up to 24 Months · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.

Read the detailed description

Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the γc gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (± 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.

OBJECTIVES

Assess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1α-hγc-OPT) expressing a γc gene.

Primary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.

Primary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (± 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:

  • The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are ≥ 50% the value seen in normal controls
  • ≥ 1000 autologous CD3+ T-cells/μl in the peripheral blood
  • ≥ 500 autologous CD4+ T-cells/μl in the peripheral blood
  • ≥ 200 autologous CD4+ CD45RA T-cells/μl in the peripheral blood

OTHER PRE-SPECIFIED OBJECTIVES:

  • Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.
  • Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg*hr/L.
  • Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include γc expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.
  • Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.
  • Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.
  • Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.
03

Conditions studied

  • Severe Combined Immunodeficiency Disease, X-linked

Keywords

  • SCID
  • SCID-X1
  • X-linked SCID
  • immunodeficiency
  • gene therapy
04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

* Treatment Eligibility Criteria:

  • Age \<2 years at the time of enrollment.
  • No prior therapy with stem cell transplantation.
  • A clinical diagnosis of SCID-X1 documented in the medical record.
  • A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
  • Age > 2 months to \< 1 year of age at the time of busulfan administration.
  • Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX.
  • Lymphocyte proliferation to phytohemagglutinin (PHA) \<10% of the lower limit of normal for the laboratory.

Treatment Exclusion Criteria:

  • Availability of a HLA matched sibling for allogeneic transplantation
  • Prior therapy with allogeneic stem cell transplantation
  • Positive for infection by genome PCR
  • Presence of a medical condition indicating that survival will be less than 16 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is to medical therapy.
  • The presence of any medical to general anesthesia and bone marrow harvest by aspiration
  • A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Treatment

    Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT

    Genetic: CL20-i4-EF1α-hγc-OPT · Drug: Busulfan · Device: CliniMacs

Interventions

  • GeneticCL20-i4-EF1α-hγc-OPT

    Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.

    Also known as: self inactivating lentiviral vector, IND 14570

  • Given intravenously (IV).

    Also known as: Busulfex®, Myleran®

  • DeviceCliniMacs

    Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.

06

What researchers measure

Primary outcomes

  1. Number of patients with adequate cell collection and processing

    The number of patients who underwent no more than two bone marrow harvests and cryopreservation of at least 1.0 million cells/kg following vector transduction.

    Time frame: Day 0

  2. Number of patients with adequate neutrophil count recovery after busulfan conditioning

    Adequate recovery is defined as absolute neutrophil count (ANC) \>500 cells/μl by day +42 unless the patient is neutropenic prior to busulfan administration.

    Time frame: Day 42 post gene transfer

  3. Number of patients without Grade 4 adverse event (AE)

    The number of patients experiencing no directly related grade 4 or greater adverse event.

    Time frame: 42 days post gene transfer

  4. Number of patients with successful reconstitution

    Reconstitution with transduced cells defined as detection of vector-marked peripheral blood cells by real time PCR at or above 0.02% VCN in total WBC.

    Time frame: 42 days post gene transfer

  5. Number of patients with treatment failure

    Treatment failure will be defined as lack of adequate cell collection and processing, lack of neutrophil count recovery by day +42, occurrence of grade 4 or greater toxicities by day +42, and/or lack of detection of \>0.02% transduced cells in peripheral blood by day +42 post gene transfer.

    Time frame: 42 days post gene transfer

Other outcomes

  1. Pharmacokinetic (PK) variables of busulfan

    Blood collections for pharmacokinetic sampling will be performed with dose 1 and used to determine dose modifications for dose 2, if needed. The specific times for blood collects will be institution specific. Summary statistics will be reported.

    Time frame: Days -2 and -1 prior to therapy

  2. Number of patients who achieve the desired therapeutic busulfan AUC

    The efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan AUC of 22 mg\*hr/L will be evaluated. The number of patients who achieve the desired therapeutic busulfan AUC will be reported

    Time frame: Day 0

  3. B-cell function evaluated by Immune response

    Evaluation may include γc expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG. Summary statistics will be reported.

    Time frame: 52 weeks post gene transfer

  4. Number of NK cells

    Evaluation will include flow cytometry evaluation of NK cell numbers. Summary statistics will be reported.

    Time frame: 52 weeks post gene transfer

  5. Vector copy number by location of vector-integration sites in sorted blood cells

    Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites. Summary statistics will be reported.

    Time frame: up to 10 years post gene transfer

  6. Event-free survival (EFS)

    Event is defined as death, requiring boost post infusion, or an oncogenic event . EFS is defined as time from busulfan infusion to event defined here with all patients surviving at the time of analysis censored.

    Time frame: from baseline up to 10 years post gene transfer

  7. Overall survival (OS)

    OS is defined as time from busulfan infusion to death with all patients surviving at the time of analysis censored.

    Time frame: up to 10 years post gene transfer

07

Study locations

3 sites
  • University of California-San Francisco
    San Francisco, California 94158, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98101, United States
08

References and documents

Publications

  • Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019 Apr 18;380(16):1525-1534. doi: 10.1056/NEJMoa1815408. PubMed 30995372 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2016 (actual). Primary completion is estimated for Oct 2027, 134 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Oct 2027 and completion Aug 2034 → Oct 2039.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 19, 2012
StartActual
Aug 17, 2016
Primary completionEst.
Oct 30, 2027was Aug 2026
CompletionEst.
Oct 30, 2039was Aug 2034
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Oct 30, 2027
Nov 16, 2026
Study completion
Aug 2034→Oct 30, 2039
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Aug 2026→Oct 30, 2027
    Study completion Aug 2034→Oct 30, 2039
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01512888
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Assisi Foundation, California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Aug 17, 2016
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2039 (estimated)
Last update
Nov 16, 2026

Study contacts

Stephen Gottschalk, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Busulfan

Start the discussion